Telix Pharmaceuticals Releases Annual Report Year Ending 2019
Telix Pharmaceuticals Limited Releases Annual Report Year Ending 2019.
Telix Pharmaceuticals and ATONCO Partner for Bladder Cancer
Telix Pharmaceuticals Limited and French company ATONCO S.A.S are pleased to announce they have entered into a Licence and Development Agreement that will enable ATONCO to investigate the use of Telix’s Molecularly Targeted Radiation (MTR) intellectual property for the treatment of non-muscle invasive bladder cancer that is resistant to standard therapies.
Telix Pharmaceuticals and AusHealth to Partner on Novel Therapeutics for Lung, Ovarian Cancer
Telix Pharmaceuticals Limited has today announced that Telix and AusHealth have entered into a collaboration and technology licensing agreement for a novel Molecularly Targeted Radiation (MTR) platform called APOMAB® intended for the treatment of ovarian and lung cancers.
Telix Pharmaceuticals to Acquire European Production Facility
Telix is pleased to announce that it has entered into a conditional purchase agreement with Eckert & Ziegler Strahlen and Medizintechnik Aktiengesellschaft to acquire a licensed radiopharmaceutical production facility in Seneffe, Belgium.
FDA Pre-NDA Meeting Outcomes : TLX591-CDx (illumet™)
Telix is pleased to share the company had a pre-NDA meeting with the United States Food and Drug Administration (FDA) on the 24th of July to discuss the Company’s plan for the submission of a New Drug Application (NDA) for TLX591-CDx, (kit for the preparation of 68Ga-PSMA, trademarked as illumet™ in the United States).
Appendix 4D Financial Report for half-year to 30th June 2019
Telix Pharmaceuticals Limited is pleased to provide appendix 4D half-year report for the six months ended 30th June 2019.
Appendix 3B – Issue of shares under Share Purchase Plan
Telix Pharmaceuticals Ltd is pleased to announce Appendix 3B – Issue of shares under Share Purchase Plan (SPP).
Telix Pharmaceuticals Announces Results of Successful SPP
Telix Pharmaceuticals Limited is pleased to advise that, at closing on Friday 16th August 2019, subscriptions under the Company’s Share Purchase Plan (“SPP”) totaled approximately $9.6 million.
Telix Pharmaceuticals Annual Report 2018
Telix Pharmaceuticals Limited is pleased to provide its Annual Report 2018.
Telix Pharmaceuticals Ltd Detailed Program Update January 2019
Telix Pharmaceuticals Limited is pleased to provide a detailed Program Update January 2019.